855-020-0300
Protocol Compendium

A Pharmacist may prescribe, via statewide drug therapy management protocol and according to rules outlined in this Division, an FDA-approved drug and device listed in the following compendium:

(1) Continuation of therapy including emergency refills of insulin (v. 06/2023)

(2) Conditions

(a) Cough and cold symptom management

(A) Pseudoephedrine (v. 06/2021);

(B) Benzonatate (v. 06/2021);

(C) Short-acting beta agonists (v. 06/2021);

(D) Intranasal corticosteroids (v. 06/2021);

(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);

(c) COVID-19 Antigen Self-Test (v. 12/2021); 

(3) Preventative care

(a) Emergency Contraception (v. 06/2021);

(b) Male and female condoms (v. 06/2021);

(c) Tobacco Cessation, Nicotine Replacement Therapy (NRT) and Non-NRT (v. 06/2022);

(d) Travel Medications (v. 06/2023);

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023); 

(g) Contraception (v. 06/2023); and 

(h) Vaccinations:

(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 2/2024); 

(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 2/2024); 

(C) Cholera (v. 2/2024); 

(D) Coronavirus 2019 (v. 2/2024); 

(E) Haemophilus Influenza type b (v. 2/2024)

(F) Hepatitis A containing vaccines (v. 2/2024); 

(G) Hepatitis B containing vaccines (v. 2/2024); 

(H) Human Papillomavirus (v. 2/2024); 

(I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 2/2024); 

(J) Influenza - Live Attenuated Influenza Vaccine 2023-24 (v. 2/2024); 

(K) Japanese Encephalitis (v. 2/2024); 

(L) Meningococcal containing vaccines (v. 2/2024); 

(M) Measles Mumps & Rubella containing vaccines (v. 2/2024); 

(N) Pneumococcal (v. 2/2024); 

(O) Polio (v. 2/2024); 

(P) Rabies (v. 2/2024); 

(Q) Respiratory Syncytial Virus (v. 2/2024);

(R) Tetanus Diphtheria containing vaccines (v. 2/2024);

(S) Typhoid (v. 2/2024); 

(T) Varicella containing vaccines (v. 2/2024);

(U) Yellow fever (v. 2/2024); 

(V) Zoster (v. 2/2024).

[Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689 & ORS 689.696
History:
BP 1-2024, temporary suspend filed 02/15/2024, effective 02/29/2024 through 08/26/2024
BP 33-2023, amend filed 12/19/2023, effective 02/01/2024
BP 11-2023, amend filed 06/13/2023, effective 06/13/2023
BP 4-2023, temporary amend filed 02/10/2023, effective 02/10/2023 through 08/08/2023
BP 56-2022, amend filed 12/20/2022, effective 02/01/2023
BP 44-2022, temporary amend filed 10/17/2022, effective 10/17/2022 through 04/14/2023
BP 31-2022, amend filed 06/15/2022, effective 06/16/2022
BP 16-2022, amend filed 04/20/2022, effective 04/20/2022
BP 34-2021, temporary amend filed 12/10/2021, effective 12/10/2021 through 06/07/2022
BP 31-2021, amend filed 12/10/2021, effective 12/10/2021
BP 22-2021, temporary amend filed 09/01/2021, effective 09/01/2021 through 02/27/2022
BP 18-2021, amend filed 06/15/2021, effective 06/15/2021
BP 96-2020, amend filed 12/23/2020, effective 12/23/2020
BP 85-2020, amend filed 08/26/2020, effective 08/27/2020
BP 7-2019, amend filed 10/15/2019, effective 10/16/2019
BP 5-2018, adopt filed 10/18/2018, effective 10/18/2018